Clinical Trial Update: Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of paclitaxel and estramustine in relapsed or refractory Non-Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Estramustine phosphate (Estracyt) (Estramustine phosphate)
• Paclitaxel (Taxol) (paclitaxel)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Lymphoma | Phase 2 | Status: COMPLETED